Dulaglutide trulicity patent expiry 2027 2028?

Trulicity® (dulaglutide) – patent status

Key take‑aways

1. Generic entry in the U.S.
   Eli Lilly’s exclusivity on the active drug and its delivery system is expected to last until 2028. After that, generic manufacturers may file for approval, provided they can demonstrate bioequivalence. The first generics are anticipated to reach the market sometime in 2028–2029, depending on FDA review timelines.

2. Patent “evergreen” extensions
   Patents can sometimes be extended through regulatory or legal mechanisms (e.g., FDA “patent term extensions” for drugs that faced review delays). Eli Lilly has applied for such extensions for dulaglutide, but the current public record indicates that the primary term still ends in 2028.

3. International differences
   The expiration dates can vary by country. In the EU, for instance, the primary patents are set to expire in 2028 as well, but some secondary patents may end in 2027. Always check the local regulatory agency for the most accurate information.

4. Clinical relevance
   Even after patents expire, the brand‑name product will often remain on the market because it is a well‑established therapy with a strong safety record. However, the introduction of cheaper generic versions could make dulaglutide more affordable for patients and payers.

Bottom line: The main patents that protect Trulicity® (both the active molecule and its delivery system) are scheduled to expire in 2028. Some related patents may finish a year earlier (2027), but generics are unlikely to reach the U.S. market until 2028–2029. If you’re tracking this for formulary decisions, keep an eye on FDA “generic filing” announcements that typically precede market entry by several months.